

Express Mail Label No.: EM 407747575US Date: July 1, 2009

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In Re Application of: Qui-Lim Choo
U.S. Appln. No.: 10/580,050
Intl. Appln. No.: PCT/US04/39333
I.A. Filing Date: 11/19/2004
Priority Date: 11/19/2003
Title: METHODS AND REAGENTS FOR
TREATING, PREVENTING AND
DIAGNOSING *BUNYAVIRUS*
INFECTION

Confirmation No.: 7391
Group Art Unit: To Be Assigned
Examiner: To Be Assigned

RESPONSE TO NOTICE TO NOTICE OF ABANDONMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the "Notice of Abandonment" we are resubmitting a response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed February 18, 2009 from the United States Patent and Trademark Office(USPTO). The applicant would like to bring to the USPTO's attention multiple responses were submitted previous to this paper listed below. Copies of said papers are also provided herewith. Enclosed herewith are the following to complete the "Notice to

Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" in the above-identified application:

- 1. COPY OF THE NOTICE OF ABANDONMENT**
- 2. COPY OF NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.**
- 3. COPY OF THE PRELIMINARY AMENDMENT SUBMITTED JANUARY 31 2008 AND MARCH 20, 2009.**
- 4. COPY OF PREVIOUSLY SUBMITTED TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
 - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
 - b. Paper Copy of the Sequence Listing (60 pages).
 - c. Copy Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
- 5. COPY OF RETURN RECEIPT POSTCARDS DATED JANUARY 31, 2008 AND MARCH 20, 2008.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: July 1, 2008

By: Regina Bautista
Regina Bautista
Registration No. 46,280

Customer No. 27476

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Corporate Intellectual Property – R338

P.O. Box 8097

Emeryville, CA 94662-8097

Telephone: (510) 923-2192

Facsimile: (510) 655-3542



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004


27476
NOVARTIS VACCINES AND DIAGNOSTICS INC.
INTELLECTUAL PROPERTY R338
P.O. BOX 8097
Emeryville, CA 94662-8097

I.A. FILING DATE	PRIORITY DATE
11/19/2004	11/19/2003



OC000000035945488

Date Mailed: 05/14/2009



NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- The sequence requirements still haven't been met.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

INDIA L EVANS

Telephone: (703) 756-1424

RSB 5/18/09 70
51835-US-PCT
7/14/09

Submitted March 20, 2008
(with copies of all documents submitted 1-31-2008)

SERIAL NO: 10580,050 FILING DATE: 11-19-04 DKT NO: PP21454.004

TITLE: Method and Reagents for Treating, preventing,...

ATTY: RSB APPLICANT: Qui-Lim Choo DATE MAILED 3-20-09

CERTIFICATE OF MAILING EXPRESS MAIL LABEL NO: EM028421462US

THE U.S. PATENT & TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:

Auth. to Charge Deposit Account No. 03-1664

Fee \$ _____ Check # 8756

Provisional Application for Patent Cover Sheet

Utility Application Transmittal

Fee Transmittal Form / Fee Calculation Sheet

1 pp Spec. 1 pp Claims 1 pp Abstract

Informal/Formal Drawings 1 sheets

Declaration 1 Signed 1 Unsigned

Application Data Sheet

Paper Sequence Listing 1 Pages

Disk Containing Sequence Listing # 1 copies

Statement to Support Filing & Submission in Accordance with 37 CFR §§1.821 - 1.825

Power of Attorney / Declaration and Power of Attorney

Assignment w/Recordation Cover Sheet 1 pages

Certificate Under 37 C.F.R. §3.73(b)

IDS with Form 1449 and _____ references

Amendment Preliminary Amend

COPY Notice to File Missing Parts Application Filing Date Granted

Petition _____

Request for Corrected Filing Receipt w/copy of Official Filing Receipt

Notice of Appeal Issue Fee Transmittal B

Change of Correspondence Address

Transmittal Letter to the U.S. Designated/Elected (DO/EO/US) Concerning a Filing Under 35 USC 371

Copy of Notification of Missing Requirements under 35 U.S.C. 371 in the (DO/EO/US)

PCT Request 1 Pages Demand (DC2)

Response NTC complies

51835-US-PCT

Customer Copy
Label 11-F, April 2004



ORIGIN (POSTAL SERVICE USE ONLY)			
PO ZIP Code <i>94018</i>	Day of Delivery <input type="checkbox"/> Next Day <input type="checkbox"/> 2nd Day <input type="checkbox"/> 2nd Del. Day	Postage <i>\$ 17.50</i>	
Date Accepted <i>3/20/09</i>	Scheduled Date of Delivery Month Day	Return Receipt Fee \$	
Mo. Day Year			
Time Accepted <input type="checkbox"/> AM <i>1650</i> <input type="checkbox"/> PM	Scheduled Time of Delivery <input type="checkbox"/> Noon <input checked="" type="checkbox"/> 3 PM	COD Fee <i>\$</i>	Insurance Fee <i>\$</i>
Military		Total Postage & Fees <i>\$ 17.50</i>	
Flat Rate <input type="checkbox"/> or Weight <i>6 lbs. 6 ozs.</i>	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	\$	
Int'l Alpha Country Code	Acceptance Emp. Initials <i>RK</i>		

CUSTOMER USE ONLY			
METHOD OF PAYMENT: <i>A 940554</i>	PHONE () <i>408-262-0797</i>	Federal Agency Acct. No. or Postal Service Acct. No.	
Express Mail Corporate Acct. No.			
FROM: (PLEASE PRINT) <i>ADVANTAGE LINING &</i>	TO: (PLEASE PRINT) <i>R 8B</i>	PHONE () <i>MAIL STOP</i>	
<i>DIAGNOSTICS INC.</i>	<i>COMMISSIONER FOR PATENTS</i>	<i>PC 604-1450</i>	
<i>CORPORATE INTELLECTUAL</i>	<i>ALBANY, NY</i>	<i>617-548-1450</i>	
<i>PROPERTY 4430</i>			
<i>PO BOX 6097</i>			
<i>ELGIN, IL</i>			
<i>PP 21454,000 (51835-45-PC)</i>			



UNITED STATES POSTAL SERVICE®

Post Office To Addressee

DELIVERY (POSTAL USE ONLY)			
Delivery Attempt Mo. Day	Time <input type="checkbox"/> AM	Employee Signature	
Delivery Attempt Mo. Day	Time <input type="checkbox"/> AM	Employee Signature	
Delivery Date Mo. Day	Time <input type="checkbox"/> PM	Employee Signature	
Delivery Date Mo. Day	Time <input type="checkbox"/> AM	Employee Signature	
<input type="checkbox"/> WAIVER OF SIGNATURE (Postage Paid Mail Only) I, the addressee or my authorized representative, acknowledge that this delivery is valid if waiver or signature is not present. I further acknowledge that delivery is made to the address or address(es) of the addressee or my authorized representative (as indicated on the label) and I authorize that delivery employee's signature constitutes valid proof of delivery.			
<input type="checkbox"/> NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday <input type="checkbox"/> Customer Signature			

FOR PICKUP OR TRACKING: Visit WWW.USPS.COM or Call 1-800-222-1811





EM 028421462 US

Mail
Label

UNITED STATES POSTAL SERVICE®

Post Office To Ad

PRESS HARD. YOU ARE MAKING 3 COPIES.

ORIGIN (POSTAL SERVICE USE ONLY)		
PO ZIP Code	Day of Delivery	Postage
	<input type="checkbox"/> Next <input type="checkbox"/> 2nd <input type="checkbox"/> 3rd Del. Day	\$
Date Accepted	Scheduled Date of Delivery	Return Receipt Fee
Mo. Day Year	Month Day	\$
Time Accepted	Scheduled Time of Delivery	COD Fee Insurance Fee
□ AM □ PM	<input type="checkbox"/> Noon <input type="checkbox"/> 3 PM	\$ \$
Flat Rate <input type="checkbox"/> or Weight	Military	Total Postage & Fees
lbs. ozs.	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	\$
Int'l Alpha Country Code		Acceptance Emp. Initials

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	<input type="checkbox"/> AM <input type="checkbox"/> PM Employee Signature
Mo. Day		
Delivery Attempt	Time	<input type="checkbox"/> AM <input type="checkbox"/> PM Employee Signature
Mo. Day		
Delivery Date	Time	<input type="checkbox"/> AM <input type="checkbox"/> PM Employee Signature
Mo. Day		
<input type="checkbox"/> WAIVER OF SIGNATURE (Domestic Mail Only) Additional merchandise insurance void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in specified location) and I authorize that delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		Customer Signature

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

X946559

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT) PHONE ()
 NOVARTIS VACCINES &
 DIAGNOSTICS INC
 CORPORATE INTELLECTUAL
 PROPERTY R338
 PO BOX 8097
 EMERYVILLE CA 94662-8097

PP 21454,0004 (51835-US-PC)

TO: (PLEASE PRINT) PHONE ()

MAIL STOP
 COMMISSIONER FOR PATENTS
 PO BOX 1450
 ALEXANDRIA VA 22313

FOR PICKUP OR TRACKING: Visit WWW.USPS.COM or Call 1-800-222-1811

201/ 300 F:21 T:12



SERIAL NO: 10580,050 FILING DATE: 11-19-04 DKT NO: PP 21454,0004
 TITLE: Method and Reagents for Treating, preventing
 ATTY: RSB APPLICANT: Quo-Lim Chou DATE MAILED: 3-20-09
 CERTIFICATE OF MAILING EXPRESS MAIL LABEL NO: EM 028421462 US

THE U.S. PATENT & TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:

Auth. to Charge Deposit Account No. 03-1664
 Fee \$ _____ Check # _____
 Provisional Application for Patent Cover Sheet
 Utility Application Transmittal
 Fee Transmittal Form / Fee Calculation Sheet
 _____ pp Spec. _____ pp Claims _____ pp Abstract
 Informal/Formal Drawings _____ sheets
 Declaration _____ Signed _____ Unsigned
 Application Data Sheet
 Paper Sequence Listing _____ Pages
 Disk Containing Sequence Listing # 1 copies
 Statement to Support Filing & Submission in
 Accordance with 37 CFR §§1.821 - 1.825
 Power of Attorney / Declaration and Power of Attorney
 Assignment w/Recordation Cover Sheet _____ pages

Certificate Under 37 C.F.R. §3.73(b)
 IDS with Form 1449 and _____ references
 Amendment Preliminary Amendment
 COPY Notice to File Missing Parts Application Filing Date Granted
 Petition _____
 Request for Corrected Filing Receipt w/copy of Official Filing Receipt
 Notice of Appeal Issue Fee Transmittal B
 Change of Correspondence Address
 Transmittal Letter to the U.S. Designated/Elected
 (DO/EO/US) Concerning a Filing Under 35 USC 371
 Copy of Notification of Missing Requirements under
 35 U.S.C. 371 in the (DO/EO/US)
 PCT Request _____ Pages Demand (DC2)
 Response NTcomply

with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" in the above-identified application:

1. **COPY OF** Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
2. **PRELIMINARY AMENDMENT.**
3. **TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
 - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
 - b. Paper Copy of the Sequence Listing (60 pages).
 - c. Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
4. **EXECUTED DECLARATIONS (6 PAGES).**
5. **RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 3/17/09

By: Regina Bautista
Regina Bautista
Registration No. 46,280

Customer No. 27476

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property – R338
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2192
Facsimile: (510) 655-3542



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050 27476 NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338 P.O. BOX 8097 Emeryville, CA 94662-8097	Qui-Lim Choo	PP021454.0004
INTERNATIONAL APPLICATION NO.		
PCT/US04/39333		
LA. FILING DATE	PRIORITY DATE	
11/19/2004	11/19/2003	

CONFIRMATION NO. 7391
371 WITHDRAWAL NOTICE

Date Mailed: 02/18/2009

EMERYVILLE-CIP
FEB 20 2009
F/F M/D Inv. RE ASG PA



OC000000034583743

Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 01/16/2007. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocaleEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

page 1 of 1

2009-02-18 09:27:06
Filing Date 51835 US PCT
Docket No 4118109
Mailed Date 2009-02-18 09:27:06



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050 27476	Qui-Lim Choo	PP021454.0004
NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338 P.O. BOX 8097 Emeryville, CA 94662-8097		INTERNATIONAL APPLICATION NO. PCT/US04/39333
		I.A. FILING DATE PRIORITY DATE 11/19/2004 11/19/2003

CONFIRMATION NO. 7391
371 FORMALITIES LETTER



OC000000034583749

Date Mailed: 02/18/2009

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004
27476 NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338 P.O. BOX 8097 Emeryville, CA 94662-8097	INTERNATIONAL APPLICATION NO. PCT/US04/39333	
	I.A. FILING DATE	PRIORITY DATE
	11/19/2004	11/19/2003

CONFIRMATION NO. 7391
371 FORMALITIES LETTER



OC000000034583749

Date Mailed: 02/18/2009

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,050	Qui-Lim Choo	PP021454.0004
27476		INTERNATIONAL APPLICATION NO.
NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338 P.O. BOX 8097 Emeryville, CA 94662-8097		PCT/US04/39333
		I.A. FILING DATE PRIORITY DATE
		11/19/2004 11/19/2003
CONFIRMATION NO. 7391 371 WITHDRAWAL NOTICE		
OC000000034583743		

Date Mailed: 02/18/2009

Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 01/16/2007. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <http://www.uspto.gov/ebc>.

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

11/19/2009 10:00 AM
R SB
File # 51835-43-POT
Due Date 4/18/09
Final Date 4/18/09
PP021454.0004

Express Mail Label No.: ED 954551195 US Date: January 31, 2008

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In Re Application of: Qui-Lim Choo

U.S. Appln. No.: 10/580,050

Intl. Appln. No.: PCT/US04/39333

I.A. Filing Date: 11/19/2004

Priority Date: 11/19/2003

Title: METHODS AND REAGENTS FOR
TREATING, PREVENTING AND
DIAGNOSING *BUNYAVIRUS*
INFECTION

Confirmation No.: 7391

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

TRANSMITTAL LETTER

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed herewith are the following documents to complete the above-identified application:

- 1. TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
 - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
 - b. Paper Copy of the Sequence Listing (60 pages).
 - c. Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
- 2. PRELIMINARY AMENDMENT.**
- 3. RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: January 31, 2008

By: Helen Lee
Helen Lee
Registration No. 39,270

Customer No. 27476

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property – R338
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2192
Facsimile: (510) 655-3542